The discovery that such adverse reactions could be prevented when IL-2 was administrated as immune complex bound to anti-IL-2 mAb opened up new therapeutic approaches for the treatment of autoimmune diseases like SLE. The gene discussed is IL2; the disease is systemic lupus erythematosus.